ARTICLE | Company News
FDA approves Melinta’s fluoroquinolone antibiotic
June 20, 2017 7:26 PM UTC
FDA approved oral and IV Baxdela delafloxacin from Melinta Therapeutics Inc. (New Haven, Conn.) to treat acute bacterial skin and skin structure infections (ABSSSIs).
Baxdela’s label includes a boxed warning that notes the risks of serious adverse reactions including tendinitis, tendon rupture, peripheral neuropathy and CNS effects. Melinta said the broad-spectrum fluoroquinolone antibiotic is active against both Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA)...
BCIQ Company Profiles